Life Sciences

Now that May is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in April – they’re ranked in order of popularity, with number one being the most viewed piece. From Laptops To Tablets: Eli Lilly Bought […]

We frequently blog about FDA Warning Letters and other regulatory and compliance issues that revolve around traditional pharmaceuticals and medical devices. However, one product segment that we haven’t yet discussed is digital health. This is because digital health products are fairly new to the market and most are still trying to figure out how FDA […]

Let’s tackle a tough one… It’s one thing to put IBM Maximo, an enterprise asset management solution, in the cloud. It’s something completely different to put IBM Maximo in an FDA-compliant cloud!  At Perficient, we don’t do the usual – we cater to the difficult and never been done before, crowd. Our cloud has been serving […]

In a recent blog post, I mentioned the three critical themes for success in the digital age, as identified by McKinsey & Company through interviews with 20 pharma executives: 

Bring out the popcorn! This Thursday, Dr. Rodney Lemery, one of our experts in drug safety and pharmacovigilance, will be delivering a webinar on the latest version of Oracle Argus Safety, the most widely used and trusted PV system on the market. This presentation is meant for everyone, whether you’re already using the system and […]

I don’t often see FDA Warning Letters issued to Institutional Review Boards (IRBs), so, when I came across this one, I thought it was worth sharing with you. This particular IRB was found to be in violation of 21 CFR Part 56.115(a)(2), related to meeting minutes, and 21 CFR Part 56.115(a)(5), related to a complete […]

If you’re an avid reader of this blog, you’ve probably seen several posts highlighting Quintiles, the world’s largest contract research organization (CRO). That’s for good reason. Not only is the global CRO at the top of its game, when it comes to running all aspects of clinical trials for their clients, they’re leading the way […]

I enjoy reading FDA Warning Letters. They’re insightful and often entertaining. Sometimes, though, they’re kind of unbelievable. And, sometimes, they’re downright nauseating. Take, for example, this letter issued on February 19, 2016 to a principal investigator (PI) based in New York. FDA inspectors found him to be in violation of 21 CFR Part 312.62(b), related […]

Last week, I wrote a post about an article published by McKinsey & Company in which they interviewed 20 pharma executives about how they’re handling digital transformation. The article was jam-packed with great information, so I wanted to highlight a few more points for you. 

In 2015, companies in all industries experienced data security breaches. From Anthem, one of the nation’s leading health benefits companies, to the UCLA Health System, all the way to Hzone, a matchmaking mobile application for HIV positive singles, no company was safe from a data breach. Increasing data privacy and security is a trend that […]

  In a recent article, McKinsey & Company shared the results of 20 interviews with leading executives in pharma about the “digital revolution.” Through the interviews, McKinsey sought to learn how pharma companies plan to stay ahead of inherent changes in the age of digital. 

  Demographics in clinical trials have always been scrutinized by the medical community and the public. Are various races, ethnicities, sexes, and ages fairly represented in trials? Does one segment respond better or worse than another to a particular treatment? These questions and more are being answered in the Drug Trials Snapshots section of the […]